Clinical trials: Cell- and Tissue-Based Therapy
Malignant Melanoma
Study of Heat Shock Protein-Peptide Complex (HSPPC-96) Versus IL-2/DTIC for Stage IV Melanoma
The primary goal of this study is to determine if people with metastatic melanoma who receive Heat Shock Protein-Peptide Complex - 96 (HSPPC-96 or Oncophage) after surgery live longer than people who may or may not have surgery…
- Trial name
- NCT00039000
- Testing
- HSPPC-96 or Oncophage
- Where
- 77 sites in United States, Australia and 7 more
- Volunteers
- 350 people
- Sponsor
- Agenus Inc.
Melanoma, Neoplasm Metastasis
Study to Compare the Efficacy and Safety of CC-5013 vs. Placebo in Subjects With Metastatic Malignant Melanoma.
Subjects are randomized to one of two treatment arms. All subjects are screened for eligibility within 28 days prior to randomization. The study consists of a treatment phase and a follow-up phase.
- Trial name
- NCT00057616
- Testing
- CC-5013
- Where
- 49 sites in Australia, Estonia and 7 more
- Volunteers
- 274 people
- Sponsor
- Celgene
Carcinoma
Data Base Project for Acquisition of Cancer Patient Data in Practices and Ambulant Therapy
The purpose of this registry is to evaluate the situation regarding ambulant therapy of cancer patients in different practices in Germany.
- Trial name
- NCT02303353
- Where
- Germany
- Volunteers
- 2,000 people
- Sponsor
- SPGO Research Mannheim GmbH
Melanoma
RBL001/RBL002 Phase I Clinical Trial
Clinical first-in-human dose escalation study evaluating the safety and tolerability of intranodal administration of an RNA-based cancer vaccine targeting two tumor-associated antigens in patients with advanced melanoma
- Trial name
- MERIT (NCT01684241)
- Testing
- RBL001/RBL002
- Where
- 4 sites in Austria, Germany
- Volunteers
- 29 people
- Sponsor
- BioNTech RNA Pharmaceuticals GmbH
Melanoma, Neoplasm Metastasis
Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects With Metastatic Malignant Melanoma
Subjects are randomized to one of two treatment arms. All subjects are screened for eligibility within 28 days prior to randomization. The study consists of a treatment phase and a follow-up phase.
- Trial name
- NCT00055562
- Testing
- CC 5013
- Where
- 31 sites in United States, Canada
- Volunteers
- 274 people
- Sponsor
- Celgene Corporation
Melanoma
TRAQinform Assessment of Immunotherapy Response
The intent of this study is to evaluate the actionable information output from the TRAQinform Immuno technology in a prospective, non-interventional clinical study.
- Trial name
- AIQ TRAQinform (NCT05819255)
- Testing
- Non-Interventional
- Where
- 2 sites in United States
- Volunteers
- 26 people
- Sponsor
- AIQ Solutions
Advanced Solid Tumor, Platinum-Resistant Ovarian Cancer
NTX-301 Monotherapy in Advanced Solid Tumours and in Combination With Platinum-based Chemotherapy in Advanced Ovarian & Bladder Cancer and in Combination With Temozolomide in High-grade Glioma
This is a Phase 1/2, open-label, dose-exploration, combination/expansion study, which will start by evaluating the safety and tolerability of NTX-301, an oral DNMT1 inhibitor, as a monotherapy in patients with advanced solid…
- Conditions
- Advanced Solid Tumor, Platinum-Resistant Ovarian Cancer, Platinum-Resistant Urothelial Carcinoma, High-grade Glioma
- Trial name
- NCT04851834
- Testing
- NTX-301, Platinum-based Chemotherapy, Temozolomide
- Where
- 2 sites in Australia
- Volunteers
- 12 people
- Sponsor
- Xennials Therapeutics Australia Pty Ltd
Non Small Cell Lung Cancer, Microbiome
BioForte Technology for in Silico Identification of Candidates for a New Microbiome-based Therapeutics and Diagnostics
The goal of the project is to develop and validate the BioForte technology. Its main functionality should be to in silico determine candidates for novel microbiome-based therapeutics and diagnostics.
- Conditions
- Non Small Cell Lung Cancer, Microbiome, Metagenome, Immunotherapy
- Trial name
- NCT04136470
- Testing
- Collection of stool, blood (PBMC) and biopsy (FFPE)
- Where
- 10 sites in Poland
- Volunteers
- 130 people
- Sponsor
- Ardigen
Glioblastoma Multiforme
A Phase I Study to Investigate Tolerability and Efficacy of ALECSAT Administered to Glioblastoma Multiforme Patients
It is the primary objective of this study to show safety and tolerability for administration of the cell based immunotherapy ALECSAT to patients with Glioblastoma brain cancer.
- Trial name
- ALECSAT-GBM (NCT01588769)
- Testing
- ALECSAT cell based immunotherapy
- Where
- Denmark
- Volunteers
- 23 people
- Sponsor
- CytoVac A/S
Ovarian, Melanoma
Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.
The present clinical trial is a dose comparison of a multi-component active immunotherapy designed to stimulate an immune reaction to specific tumor associated antigens which are highly expressed on a large number of solid…
- Conditions
- Ovarian, Melanoma, Renal, Prostate
- Trial name
- NCT00423254
- Testing
- PSMA/PRAME
- Where
- 5 sites in United States
- Volunteers
- 12 people
- Sponsor
- Mannkind Corporation
Brest Cancer, Lung Cancer (NSCLC)
The CCANED-CIPHER Study: Early Cancer Detection and Treatment Response Monitoring Using AI-Based Platelet and Immune Cell Transcriptomic Profiling
The purpose of the CCANED-CIPHER study is to develop and validate an AI-based blood test for early cancer detection and to monitor treatment effectiveness in cancer patients.
- Conditions
- Brest Cancer, Lung Cancer (NSCLC), Pancreatic Cancer, Adult, Prostate Cancers
- Trial name
- CCANED-CIPHER (NCT06717295)
- Testing
- DiNanoQ: A multi-cancer early detection (MCED) blood test, DiNanoTrack: Therapeutic Response Monitoring Blood Test
- Where
- 4 sites in Argentina, Nigeria and 1 more
- Volunteers
- 6,000 people, healthy volunteers welcome
- Sponsor
- Javier Toledo
Solid Tumor, Soft Tissue Sarcoma
A Study of CCT301-59 CAR T Therapy in Adult Subjects With Recurrent or Refractory Solid Tumors
This clinical study is to investigate the safety and tolerability of CAR modified autologous T cells (CCT301-59) in subjects with recurrent or refractory solid tumors.
- Conditions
- Solid Tumor, Soft Tissue Sarcoma, Gastric Cancer, Pancreatic Cancer
- Trial name
- CAR (NCT03960060)
- Testing
- CCT301-59
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Shanghai PerHum Therapeutics Co., Ltd.
Melanoma
Talimogene Laherparepvec With Pembrolizumab in Melanoma Following Progression on Prior Anti-PD-1 Based Therapy (MASTERKEY-115) (Mk-3475-A07/KEYNOTE-A07).
This is a phase 2, open-label, single-arm, multicenter clinical trial designed to evaluate the efficacy and safety of talimogene laherparepvec in combination with pembrolizumab following disease progression on prior…
- Trial name
- NCT04068181
- Testing
- Talimogene laherparepvec, Pembrolizumab
- Where
- 46 sites in United States, Australia and 9 more
- Volunteers
- 72 people
- Sponsor
- Amgen
Stage IV Non-small Cell Lung Cancer, Stage IV Malignant Melanoma
Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments
The PROPHETIC study is a prospective, multi-center, international clinical study aimed at developing an algorithm to predict patient outcomes.
- Conditions
- Stage IV Non-small Cell Lung Cancer, Stage IV Malignant Melanoma, Stage IV Small Cell Lung Cancer, Stage III Unresectable Non-Small Cell Lung Cancer
- Trial name
- PROPHETIC (NCT04056247)
- Testing
- Plasma sample collection
- Where
- 41 sites in United States, Germany and 3 more
- Volunteers
- 10,000 people
- Sponsor
- OncoHost Ltd.
Metastatic Melanoma, BRAF V600 Mutation Positive
UK ENcorafenib and BInimetinib Real-world Study in Melanoma
This is a prospective longitudinal multi-centre observational study conducted in the United Kingdom, in patients with metastatic cutaneous BRAF V600 mutation-positive melanoma assigned to receive encorafenib and binimetinib.
- Trial name
- UK-EnBiRiM (NCT07022457)
- Testing
- Encorafenib + Binimetinib
- Where
- 7 sites in United Kingdom
- Volunteers
- 50 people
- Sponsor
- Pierre Fabre Ltd
Advanced Melanoma, Stage III and IV Melanoma
Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma.
A dose comparison of a multi-component active immunotherapy designed to stimulate an immune reaction to specific tumor associated antigens which are highly expressed on melanomas.
- Trial name
- NCT00688090
- Testing
- Biological: MKC1106-MT, Biological: MKCC1106-MT
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- Mannkind Corporation
Glioblastoma Multiforme
Dendritic Cell Cancer Vaccine for High-grade Glioma
A randomised, open-label, 2-arm, multi-centre, phase II clinical study with one group receiving standard therapy with Temozolomide, radiotherapy, and Trivax; and a control group receiving standard therapy with Temozolomide and…
- Trial name
- GBM-Vax (NCT01213407)
- Testing
- Trivax, Temozolomide, Surgery, Radiotherapy, Temozolomide, Surgery, Radiotherapy
- Where
- 8 sites in Austria
- Volunteers
- 87 people
- Sponsor
- Activartis Biotech
Melanoma
A Comparison of Nivolumab-based Treatments in a Real-world PD-L1 Positive Metastatic Melanoma Population in the US
The goal of this study is to describe patient characteristics, treatment outcomes and adverse events for patients with metastatic melanoma testing positive for PD-L1 expression treated first line (1L) with either nivolumab and…
- Trial name
- NCT03732560
- Testing
- Non-Interventional
- Where
- United States
- Volunteers
- 600 people
- Sponsor
- Bristol-Myers Squibb
Advanced or Metastatic Solid Tumor, Pancreatic Ductal Adenocarcinoma
AB122 Platform Study
This is a phase 1, non-randomized open-label, multicenter platform study designed to evaluate the tolerability and safety of AB122 in patients with malignancies specified in each cohort.
- Conditions
- Advanced or Metastatic Solid Tumor, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Non-small Cell Lung Cancer
- Trial name
- NCT04999761
- Testing
- AB122, TAS-116, TAS-120
- Where
- 9 sites in Japan
- Volunteers
- 917 people
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
Melanoma
BO-112 With Pembrolizumab in Unresectable Malignant Melanoma
This is a phase 2, single arm, open label, adaptive design study to determine the preliminary anti-tumor activity and confirm the safety of IT BO-112 in combination with intravenous (IV) pembrolizumab.
- Trial name
- SPOTLIGHT203 (NCT04570332)
- Testing
- BO-112 plus pembrolizumab, Tissue Biopsies
- Where
- 19 sites in France, Spain
- Volunteers
- 42 people
- Sponsor
- Highlight Therapeutics